Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.

导出 OA

翻译打印收藏纠错

作者： Jia,Jin ^[1] ; Dongmei,Ji ^[2] ; Zuguang,Xia ^[1] ; Kai,Xue ^[2] ; Qunling,Zhang ^[1] ; Yizhen,Liu ^[2] ; Junning,Cao ^[3] ; Xiaonan,Hong ^[1] ; Juan J,Gu ^[2] ; Ye,Guo ^[1] ; Fangfang,Lv ^[2]

作者单位： Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. ^[1] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. ^[2] Department of Hematology, Shanghai Jiao Tong University School of Medicine, Affiliated Ruijin Hospital, Shanghai, 200025, China. ^[3] Oncology Department, Northern Jiangsu People;s Hospital; Cancer Institute affiliated to Northern Jiangsu People's Hospital; Medical College, Yangzhou University, Yangzhou, 255000, Jiangsu Province, China. ^[4] Department of Oncology, Shanghai East Hospital, Tongji University, Shanghai, 200120, China. pattrickguo@gmail.com. ^[5] Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. lvff80@163.com. ^[6] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. lvff80@163.com. ^[7]

关键词 Diffuse large B-cell lymphoma Limited stage Positron emission tomography Prognosis